We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent e
27 Nov 2025
Percheron Therapeutics:Phase II visibility drives valuation upgrade
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Percheron Therapeutics:Phase II visibility drives valuation upgrade
Percheron Therapeutics Limited (PER:ASX) | 0 0 0.0% | Mkt Cap: 6.18m
- Published:
27 Nov 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
8 -
We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent e